While some studies with Alzheimer’s disease mouse models have suggested that CX3CR1 and CCR2 play a role in the progression of disease [49–51], we determined that having a single copy of either gene does not alter plaque deposition or microglial CD45 reactivity (Additional file 3 A-E). This evidence concerns the gene CCR2 and early-onset autosomal dominant Alzheimer disease.